drugset
drugset / Trial / NCT04438044

A Study to Evaluate ICP-022 in Patients With R/R PCNSL and SCNSL

NCT04438044 ↗

Phase 2 Unknown 61 enrolled Beijing InnoCare Pharma Tech Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

The phase II clinical study is to investigate the safety, tolerability, efficacy and pharmacokinetics of ICP-022.

Timeline

Start
2019-06-18
Primary completion
2023-12-31
Completion
2023-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Orelabrutinib Small molecule 150 mg —

Indications

central nervous system non-hodgkin lymphoma